P14 Pharmacokinetic and pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in a murine thigh infection model

Yokoyama, Yuta; Matsumoto, Kayoko; Watanabe, Erika; Shigemi, Akari; Umezaki, Yasuhiro; Takeshita, Akira; Nakamura, Kōichi; Okuno, Mayuko; Ikawa, Kazuro; Morikawa, Norifumi; Takeda, Yasuo

doi:10.1016/s0924-8579(13)70259-0

Search citation statements

Order By: Relevance

Paper Sections

Select...

Accepted Manuscript1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an example, based on murine thigh and lung infection models of A. baumannii, PK/PD analysis of sulbactam demonstrated that the %fT >MIC is most predictive of bacterial killing [129]. The authors concluded that sulbactam was sufficiently bactericidal when a %fT >MIC of >60% against A. baumannii thigh infection and >40% against A. baumannii lung infection was achieved.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation

Lim

Sime

Roberts

2019

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Highlights  In vitro synergy was seen in only a portion of MDR A. baumannii strains tested.  Majority of observational studies did not show added benefits of combination therapy.  No strong RCT data to support combination therapy.  Some novel agents are promising options for the treatment of MDR A. baumannii.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%